[{"id":"f04b08fb-05c4-417b-89d2-7c1a679e6dfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06026657","created_at":"2023-09-07T16:09:37.228Z","updated_at":"2024-07-02T16:35:19.941Z","phase":"Phase 1/2","brief_title":"Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT06026657","lead_sponsor":"Margaret Gatti-Mays","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-09"},{"id":"67cb2321-8f2b-4de1-85ec-a7a438f90472","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588453","created_at":"2022-10-20T14:11:48.048Z","updated_at":"2024-07-02T16:35:58.437Z","phase":"Phase 1/2","brief_title":"Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain","source_id_and_acronym":"NCT05588453","lead_sponsor":"Kari Kendra","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • UD TGFbetai NK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2022-12-29"}]